NR1H4 and Hepatic fibrosis: A novel FXR agonist, EDP-305, also demonstrated a potent effect in terms of reducing liver fibrosis triggered by metabolic stress, bile duct ligation, and methionine-choline deficient (MCD) diet in rodent models (77, 78).